Emergent Biosolut Stock Price To Earning
| ER4 Stock | EUR 8.22 0.24 2.84% |
EMERGENT BIOSOLUT fundamentals help investors to digest information that contributes to EMERGENT BIOSOLUT's financial success or failures. It also enables traders to predict the movement of EMERGENT Stock. The fundamental analysis module provides a way to measure EMERGENT BIOSOLUT's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EMERGENT BIOSOLUT stock.
EMERGENT |
EMERGENT BIOSOLUT Company Price To Earning Analysis
EMERGENT BIOSOLUT's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, EMERGENT BIOSOLUT has a Price To Earning of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
| All Next | Launch Module |
EMERGENT Fundamentals
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B | |||
| Total Asset | 3.17 B | |||
| Z Score | 2.4 | |||
| Net Asset | 3.17 B |
About EMERGENT BIOSOLUT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EMERGENT BIOSOLUT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EMERGENT BIOSOLUT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EMERGENT BIOSOLUT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.